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Stress increases the risk for major depressive disorder
(MDD), overeating, and alcohol dependence (AD). The
neuropeptide Y system is one of the best-known
modulators of the stress response, and some of its effects
are mediated through the neuropeptide Y receptor Y2
(NPY2R). The functional NPY2R variant rs6857715 (C-599T)
has been implicated in both obesity and AD, but with
opposing alleles. The present study explored whether
rs6857715 is also associated with MDD. Analysis of the
overall sample (595 MDD cases; 1295 controls) showed an
association with the AD risk allele C [P= 0.020, odds ratio
(OR) (C-allele)= 1.18]. The association remained significant
after excluding MDD patients with AD/alcohol abuse
[P= 0.038, OR (C-allele)= 1.18]; increased weight/appetite
[P= 0.006, OR (C-allele)= 1.23]; or both [P= 0.008, OR (C-
allele)= 1.25]. The present findings suggest that the NPY2R
rs6857715 C-allele makes a genuine contribution
toward MDD. Psychiatr Genet 27:34–37 Copyright © 2017
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Stress increases the risk for major depressive disorder
(MDD), alcohol dependence (AD), and obesity (Kendler
et al., 1999; Sinha and Jastreboff, 2013). These conditions
manifest in both isolated and comorbid states. Here, epi-
demiological studies have reported comorbidity between
MDD and AD (Petrakis et al., 2002; Hasin et al., 2005) and
between MDD and obesity (Petry et al., 2008; de Wit et al.,
2010). In humans and animals, one of the most widely
reported mediators of resilience to stress is neuropeptide Y
(NPY) (Hirsch and Zukowska, 2012; Sah and Geracioti,
2013). NPY exerts some of its effects through the neuro-
peptide Y receptor Y2 (NPY2R). Genetic variation in
NPY2R may thus determine individual response to stress
and the propensity to stress-induced disorders (Enman
et al., 2015). Genetic studies have reported an association
between a functional variant in the NPY2R promoter
(rs6857715; synonym: C-599T; higher expression reported
for the rs6857715 T-allele (Wei et al., 2013)) and both
obesity (Siddiq et al., 2007) and AD [Frank et al., 2012
(rs6857715 P= 0.005, odds ratio (OR) (C-allele)= 1.16);
Wetherill et al., 2008]. For further information, see
Supplementary Text, Supplemental digital content 1
(http://links.lww.com/PG/A167) and Supplementary figs S2,
Supplemental digital content 1 (http://links.lww.com/PG/
A167); S3, Supplemental digital content 1 (http://links.lww.
com/PG/A167); S4, Supplemental digital content 1 (http://
links.lww.com/PG/A167); and S5, Supplemental digital con-
tent 1 (http://links.lww.com/PG/A167). However, risk was
conferred by the T-allele in obesity and the C-allele in AD.
To our knowledge, no candidate study to date has tested
whether rs6857715 is also associated with MDD.
The aim of the present study were two-fold. First, we
investigated whether the NPY2R variant rs6857715 is
associated with MDD. Second, we investigated whether
this association is genuine or instead because of sub-
groups of MDD patients with comorbid AD/alcohol
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abuse or increased appetite/weight. Given the previously
reported association of the C-allele with AD and of the
T-allele with obesity, we hypothesized that MDD
patients with AD/alcohol abuse would show increased
C-allele frequency, whereas MDD patients with
increased appetite/weight would show increased T-allele
frequency in comparison with MDD patients without
these comorbid conditions.
Materials and methods
Participants
The present German sample comprised 595 MDD
patients and 1295 population-based controls. Data on
AD/alcohol abuse were available for 537 MDD patients
and 56 MDD patients showed one of these disorders.
Data on appetite increase and/or weight gain were
available for 594 MDD patients and 84 MDD patients
showed one of these features. Thirteen MDD patients
showed both AD/alcohol abuse and increased weight/
appetite.
In patients, clinical symptoms and lifetime ‘best esti-
mate’ diagnoses of MDD, AD, and alcohol abuse were
assessed using multiple sources of information including
the Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)
Axis I Disorders (First et al., 1994); medical records; and
information obtained using the family history method.
The items ‘appetite increase’ and ‘weight gain’ were
assessed using the Structured Clinical Interview for
DSM-IV Axis I Disorders and patients were asked to
indicate whether or not they considered these changes to
have been secondary to medication. The items were only
rated as present in individuals for whom appetite increase
and/or weight gain could be attributed to the diagnosis
per se and not to medication. Diagnosis was assigned
according to the DSM-IV criteria. In each case, a con-
sensus diagnosis was assigned by two raters. All patients
had a history of at least one episode of MDD severe
enough to warrant hospitalization.
The study was approved by the respective local ethics
committees and all participants provided written
informed consent before inclusion.
Single nucleotide polymorphism selection and
genotyping
The NPY2R promoter variant rs6857715 was selected as it is
reported to confer allele-specific expression differences
in vitro (Wei et al., 2013). In addition, rs6857715 has been
associated with AD and obesity (Siddiq et al., 2007;
Wetherill et al., 2008; Frank et al., 2012; Supplementary
Text, Supplemental digital content 1, http://links.lww.com/
PG/A167 and Supplementary fig. S5, Supplemental digital
content 1, http://links.lww.com/PG/A167). Detailed informa-
tion on genotyping is provided in Rietschel et al. (2010).
Experimental genotyping cluster plots for rs6857715 are
shown in Supplementary fig. S1, Supplemental digital
content 1 (http://links.lww.com/PG/A167).
Statistical analysis
Power calculations were performed using the Genetic
Power Calculator (Purcell et al., 2003; http://pngu.mgh.har
vard.edu/ ~ purcell/gpc/cc2.html) using a multiplicative model
of inheritance; a disease/marker allele frequency of 0.61
(1000 Genomes CEU reference sample; http://www.ncbi.
nlm.nih.gov/projects/SNP/snp_ref.cgi?rs= 6857715); a lifetime
prevalence of major depressive episodes in Germany of
around 10% (Kessler and Bromet, 2013); a control : case
ratio of 2.18 (D′= 1) between disease and marker allele;
and a significance level of α= 0.05. The power of the
sample to detect association with MDD ranged from 53 to
more than 80% depending on the proposed effect size. For
a proposed effect size of OR (C-allele)= 1.16, as based on
the association with AD (Frank et al., 2012), the power was
53%. For a proposed effect size of OR (T-allele)= 1.345, as
based on the association with obesity (Siddiq et al., 2007),
the power was 98%. In Siddiq et al. (2007), the OR was
calculated from the genotype counts of 204/208/67 obese
adults and 475/378/85 controls. The minimum effect size
detectable in the present sample is OR= 1.23.
Deviation from Hardy–Weinberg equilibrium (HWE)
was calculated using an exact test (http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl). Association testing for rs6857715 was per-
formed using the Armitage Trend Test (http://ihg.gsf.de/
cgi-bin/hw/hwa1.pl).
Results
Genotype counts, allele frequencies, and deviation from
HWE results are shown in Table 1 (Supplementary fig.
S4, Supplemental digital content 1, http://links.lww.com/
PG/A167). Distribution of genotypes did not deviate from
HWE (Table 1).
Comparison of all MDD patients (N= 595) versus con-
trols (N= 1295) showed a significant association between
MDD and the C-allele of rs6857715 [P= 0.020, OR (C-
allele)= 1.18]. This association remained significant
when the analysis was restricted to MDD patients with-
out AD/alcohol abuse versus controls [P= 0.038, OR (C-
allele)= 1.18]; MDD patients without increased weight/
appetite versus controls [P= 0.006, OR (C-allele)= 1.23];
and MDD patients with neither AD/alcohol abuse nor
increased weight/appetite versus controls [P= 0.008, OR
(C-allele)= 1.25]. No significant association was found in
a case-only analysis of MDD patients without AD/alcohol
abuse versus MDD patients with AD/alcohol abuse [P
(one sided)= 0.302, OR (C-allele)= 1.11]. Comparison of
MDD patients without increased weight/appetite versus
MDD patients with increased weight/appetite almost
reached significance [P (one sided)= 0.054, OR (T-
allele)= 1.31] (Table 2).
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Discussion
The present analyses showed a significant association
between MDD and the C-allele of the NPY2R promoter
variant rs6857715, that is, the previously reported risk
allele for AD. Exclusion of subgroups showed that this
association is genuinely attributable to MDD and not to
comorbid AD/alcohol abuse or increased weight/appetite.
As hypothesized, the MDD patient group with increased
weight/appetite showed a higher T-allele frequency than
the MDD patient group without increased weight/
appetite. This difference just failed to reach significance
[P (one sided)= 0.054], which may have been attribu-
table to the small sample size. However, if a large pro-
portion of our MDD patients had had increased weight/
appetite, the contrasting allelic effects on MDD and
weight/appetite might have obscured the detection of
any association.
A significant change in weight and/or appetite is a key
diagnostic feature of MDD. Although significant loss of
weight and/or decrease in appetite are typical features of
so-called endogenous depression (Paykel, 2008), increased
weight/appetite are reported by more than 40% of patients
with atypical depression (Sullivan et al., 1998; Thase, 2007).
Research has shown that atypical depression is the most
common form of depression in outpatient psychiatry
(Nierenberg et al., 1998; Singh and Williams, 2006). The
term ‘atypical’ is used to distinguish this form of illness
from the more severe ‘endogenous’ depression phenotype,
which was the norm at the time when depression was rarely
diagnosed in outpatients (American Psychiatric Association,
2013). The concept of endogenous versus reactive/atypical
depression has been the subject of contentious debate for
decades and has been abandoned because of lack of con-
sistent biological support and therapeutic implications
(Paykel, 2008). However, clearly measurable differences
between patient subgroups, such as weight gain/loss, could
facilitate dissection of clinical heterogeneity for the pur-
poses of genetic studies.
As differences in the peptide NPY regulate both stress and
food intake (Maniam and Morris, 2012), T-allele carriers
may constitute a specific group of patients who are more
likely to react to stress (e.g. stressful life events and/or
MDD) by increased appetite/weight gain than is the case
for C-allele carriers. Animal studies support this hypothesis
as they have shown that stress upregulates Npy2r in a
glucocorticoid-dependent manner and that upregulated
Npy2r stimulates fat angiogenesis, leading to a 50%
increase in visceral fat within a 2-week period. In contrast,
Npy2r pharmacological inhibition or knockdown prevents
the accumulation of fat under stress (Kuo et al., 2007, 2008).
The higher NPY2R expression reported for the T-allele
(Wei et al., 2013) is consistent with such a hypothesis. To
investigate the role of the T-allele in atypical depression,
large longitudinal studies of stress are warranted.
Table 1 Number of individuals per group, rs6857715 genotype counts, allele frequencies, and deviation from Hardy–Weinberg equilibrium
Group/subgroup Number of individuals Genotype counts (CC, CT, TT) Allele frequency (C) HWEc
MDD patients 595 240, 279, 76 0.64 0.79
MDD patients with appetite increase/weight gaina 84 30, 38, 16 0.58 0.51
MDD patients without appetite increase/weight gaina 510 210, 240, 60 0.65 0.56
MDD patients with AD/alcohol abuseb 56 25, 24, 7 0.66 0.77
MDD patients without AD/alcohol abuseb 481 191, 230, 60 0.64 0.49
MDD patients without appetite increase/weight gain and without AD/alcohol
abuse (MDD only)
414 171, 196, 47 0.65 0.45
Population-based controls 1295 465, 619, 211 0.60 0.86
AD, alcohol dependence; HWE, Hardy–Weinberg equilibrium; MDD, major depressive disorder.
aData were available for 594 of the 595 patients.
bData were available for 537 of the 595 patients.
cHWE exact test P-values (according to http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Table 2 P-values and effect sizes
Comparison groups/subgroups P-valuea Effect sizeb
MDD patients versus population-based controls P=0.020 (two sided) OR (C-allele)=1.18
CI=1.03–1.36
MDD patients without appetite increase/weight gain versus population-based controls P=0.006 (two sided) OR (C-allele)=1.23
CI=1.06–1.43
MDD patients without AD/alcohol abuse versus population-based controls P=0.038 (two sided) OR (C-allele)=1.18
CI=1.01–1.37
MDD patients without appetite increase/weight gain and without AD/alcohol abuse versus population-based controls
(MDD only)
P=0.008 (two sided) OR (C-allele)=1.25
CI=1.06–1.47
MDD patients with appetite increase/weight gain versus MDD patients without appetite increase/weight gain P=0.109 (two sided)
P=0.054 (one sided)
OR (T-allele)=1.31
CI=0.94–1.83
MDD patients with AD/alcohol abuse versus MDD patients without AD/alcohol abuse P=0.604 (two sided)
P=0.302 (one sided)
OR (C-allele)=1.11
CI=0.74–1.68
AD, alcohol dependence; CI, confidence interval; MDD, major depressive disorder; OR, odds ratio.
aArmitage Trend Test P-values (according to http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
bAllelic OR and CI (according to http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
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Conclusion
The present findings in MDD patients with a history of
inpatient treatment support the hypothesis that the NPY2R
variant rs6857715 is implicated not only in AD and obesity
but also in MDD. Furthermore, our findings suggest that
homogeneity in terms of MDD symptoms such as weight
gain may facilitate genetic research into depression. In this
context, it would be of interest to include information on
appetite/weight increase in the Psychiatric Genomics
Consortium MDD genome-wide association study analysis.
In a previous mega-analysis, the Psychiatric Genomics
Consortium included both inpatients and outpatients, and
identified no association between this variant and the cate-
gorical diagnosis MDD (P=0.590; Major Depressive
Disorder Working Group of the Psychiatric GWAS
Consortium et al., 2013; http://www.med.unc.edu/pgc/downloads).
Further investigation of stress-related phenotypes may gen-
erate insights into the mechanisms acting across somatic and
psychiatric diagnoses.
Acknowledgements
The study was supported by the German Federal Ministry of
Education and Research (BMBF) within the context of the
following projects: (i) the Integrated Genome Research
Network (IG) MooDS of the German National Genome
Research Network plus (NGFNplus) (grant 01GS08144 to
Sven Cichon and Markus M. Nöthen; grant 01GS08147 to
Marcella Rietschel); (ii) the Integrated Network IntegraMent
(Integrated Understanding of Causes and Mechanisms in
Mental Disorders; grant 01ZX1314A to Sven Cichon and
Markus M. Nöthen, grant 01ZX1314G to Marcella
Rietschel); and (iii) SysMedAlcoholism (Alcohol Addiction: A
Systems-Oriented Approach, grant 01ZX1311A). The latter
two projects are being conducted under the auspices of the
BMBF e:Med Systems Medicine Programme. Support was
also provided by the German Research Foundation (DFG
Exzellenzinitiative II to J.S. and DFG TR 920/2-1 to J.T.).
Markus M. Nöthen is a member of the DFG-funded
Excellence-Cluster ImmunoSensation. Marcella Rietschel
and Stephanie H. Witt are members of the Collaborative
Research Center SFB636 of the University of Heidelberg.
The study was also supported by the German Research
Foundation (DFG; grant FOR2107; RI908/11-1 to M.R.;
NO246/10-1 to M.M.N.).
Conflicts of interest
There are no conflicts of interest.
References
American Psychiatric Association (2013). Diagnostic and Statistical Manual of
Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.
De Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P (2010).
Depression and obesity: a meta-analysis of community-based studies.
Psychiatry Res 178:230–235.
Enman NM, Sabban EL, McGonigle P, van Bockstaele EJ (2015). Targeting the
neuropeptide Y system in stress-related psychiatric disorders. Neurobiol
Stress 1:33–43.
First MB, Spitzer RL, Gibbon M, Williams JBW (1994). Structured Clinical
Interview for DSM-IV Axis I Disorders. New York: New York State Psychiatric
Institute, Biometrics Research.
Frank J, Cichon S, Treutlein J, Ridinger M, Mattheisen M, Hoffmann P (2012).
Genome-wide significant association between alcohol dependence and a
variant in the ADH gene cluster. Addict Biol 17:171–180.
Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major
depressive disorder: results from the National Epidemiologic Survey on
Alcoholism and Related Conditions. Arch Gen Psychiatry 62:1097–1106.
Hirsch D, Zukowska Z (2012). NPY and stress 30 years later: the peripheral view.
Cell Mol Neurobiol 32:645–659.
Kendler KS, Karkowski LM, Prescott CA (1999). Causal relationship between
stressful life events and the onset of major depression. Am J Psychiatry
156:837–841.
Kessler RC, Bromet EJ (2013). The epidemiology of depression across cultures.
Annu Rev Public Health 34:119–138.
Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, et al. (2007).
Neuropeptide Y acts directly in the periphery on fat tissue and mediates
stress-induced obesity and metabolic syndrome. Nat Med 13:803–811.
Kuo LE, Czarnecka M, Kitlinska JB, Tilan JU, Kvetnanský R, Zukowska Z (2008).
Chronic stress, combined with a high-fat/high-sugar diet, shifts sympathetic
signaling toward neuropeptide Y and leads to obesity and the metabolic
syndrome. Ann N Y Acad Sci 1148:232–237.
Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, et al., Major
Depressive Disorder Working Group of the Psychiatric GWAS Consortium
(2013). A mega-analysis of genome-wide association studies for major
depressive disorder. Mol Psychiatry 18:497–511.
Maniam J, Morris MJ (2012). The link between stress and feeding behaviour.
Neuropharmacology 63:97–110.
Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M (1998). Course and
treatment of atypical depression. J Clin Psychiatry 59 (Suppl 18):5–9.
Paykel ES (2008). Basic concepts of depression. Dialogues Clin Neurosci
10:279–289.
Petrakis L, Gonzalez G, Rosenheck R, Krystal J (2002). Comorbidity of alcoholism
and psychiatric disorders: an overview. Alcohol Res Health 26:81–89.
Petry NM, Barry D, Pietrzak RH, Wagner JA (2008). Overweight and obesity are
associated with psychiatric disorders: results from the National Epidemiologic
Survey on Alcohol and Related Conditions. Psychosom Med 70:288–297.
Purcell S, Cherny SS, Sham PC (2003). Genetic Power Calculator: design of
linkage and association genetic mapping studies of complex traits.
Bioinformatics 19:149–150.
Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R, et al.
(2010). Genome-wide association-, replication-, and neuroimaging study
implicates HOMER1 in the etiology of major depression. Biol Psychiatry
68:578–585.
Sah R, Geracioti TD (2013). Neuropeptide Y and posttraumatic stress disorder.
Mol Psychiatry 18:646–655.
Siddiq A, Gueorguiev M, Samson C, Hercberg S, Heude B, Levy-Marchal C, et al.
(2007). Single nucleotide polymorphisms in the neuropeptide Y2 receptor
(NPY2R) gene and association with severe obesity in French White subjects.
Diabetologia 50:574–584.
Singh T, Williams K (2006). Atypical depression. Psychiatry (Edgmont) 3:33–39.
Sinha R, Jastreboff AM (2013). Stress as a common risk factor for obesity and
addiction. Biol Psychiatry 73:827–835.
Sullivan PF, Kessler RC, Kendler KS (1998). Latent class analysis of lifetime
depressive symptoms in the national comorbidity survey. Am J Psychiatry
155:1398–1406.
Thase ME (2007). Recognition and diagnosis of atypical depression. J Clin
Psychiatry 68 (Suppl 8):11–16.
Wei Z, Zhang K, Wen G, Balasubramanian K, Shih PA, Rao F, et al. (2013).
Heredity and cardiometabolic risk: naturally occurring polymorphisms in the
human neuropeptide Y(2) receptor promoter disrupt multiple transcriptional
response motifs. J Hypertens 31:123–133.
Wetherill L, Schuckit MA, Hesselbrock V, Xuei X, Liang T, Dick DM, et al. (2008).
Neuropeptide Y receptor genes are associated with alcohol dependence,
alcohol withdrawal phenotypes, and cocaine dependence. Alcohol Clin Exp
Res 32:2031–2040.
Association between NPY2R and MDD Treutlein et al. 37
